OAM
SRPT icon

Oppenheimer Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Oppenheimer Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,079
Closed -$496K – 1186
2024
Q4 		$496K Sell
4,079
-378
-8% -$46.3K 0.01% 863
2024
Q3 		$557K Buy
4,457
+145
+3% +$20K 0.01% 853
2024
Q2 		$681K Buy
4,312
+708
+20% +$91K 0.01% 786
2024
Q1 		$467K Buy
3,604
+874
+32% +$107K 0.01% 851
2023
Q4 		$263K Sell
2,730
-1,003
-27% -$96.2K ﹤0.01% 1027
2023
Q3 		$453K Buy
3,733
+468
+14% +$52.9K 0.01% 872
2023
Q2 		$374K Buy
+3,265
New +$421K 0.01% 929
2021
Q1 		– Sell
-1,277
Closed -$218K – 1204
2020
Q4 		$218K Sell
1,277
-212
-14% -$31.4K ﹤0.01% 1057
2020
Q3 		$210K Buy
+1,489
New +$226K ﹤0.01% 1019
2020
Q2 		– Sell
-320
Closed -$32K – 1397
2020
Q1 		$32K Sell
320
-7
-2% -$800 ﹤0.01% 1330
2019
Q4 		$42K Sell
327
-2
-0.6% -$202 ﹤0.01% 1366
2019
Q3 		$25K Buy
329
+1
+0.3% +$118 ﹤0.01% 1438
2019
Q2 		$50K Sell
328
-28
-8% -$3.4K ﹤0.01% 1376
2019
Q1 		$42K Sell
356
-110
-24% -$14.1K ﹤0.01% 1381
2018
Q4 		$51K Buy
+466
New +$58.3K ﹤0.01% 1341
2017
Q4 		– Sell
-99
Closed -$4K – 1432
2017
Q3 		$4K Buy
+99
New +$3.96K ﹤0.01% 1592

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Oppenheimer Asset Management's SRPT Position: Q1 2025 in Review

Oppenheimer Asset Management sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 4,079 shares — an estimated $496K sold.

Oppenheimer Asset Management first reported a position in SRPT in Q3 2017 and held it in 16 quarters. The position peaked at $681K in Q2 2024. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

  • Oppenheimer Asset Management reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Oppenheimer Asset Management sold 4,079 Sarepta Therapeutics shares in Q1 2025, an estimated $496K.
  • Oppenheimer Asset Management first reported a position in Sarepta Therapeutics in Q3 2017 and held it in 16 quarters.
  • Oppenheimer Asset Management's Sarepta Therapeutics position peaked at $681K in Q2 2024.
  • 430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Oppenheimer Asset Management's 13F filing for Q1 2025, filed 23 Apr 2025.